


**AMENDMENTS TO THE CLAIMS**

Please amend claims 3, 4, 5, 6, 11, 12, and 13 as follows:

1. **(Canceled)**

2. **(Canceled)**

3. **(Previously Presented)** An anti-inflammatory compound comprising the following structure:



wherein

$X_a$  is a membrane translocation domain comprising from 6 to 15 amino acid residues;

$X_1$  is L, A, I or nor-leucine (Nle);

$X_2$  is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropyl-A);

$X_3$  is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cyclohexyl-alanine (Cha);


$X_4$  is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

$X_5$  is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

$X_6$  is L, A, I, or nor-leucine (Nle),

wherein the anti-inflammatory compound is less than 100 amino acids in length.

4. **(Currently Amended)** ~~The anti-inflammatory compound of claim 3, wherein  $X_a$  is the amino acid sequence TA~~ An anti-inflammatory compound comprising the following structure:



wherein

$X_a$  is Thr-Ala;

$X_1$  is L, A, I or nor-leucine (Nle);

$X_2$  is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropyl-A);

$X_3$  is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cyclohexyl-alanine (Cha);

$X_4$  is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

X<sub>5</sub> is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

X<sub>6</sub> is L, A, I, or nor-leucine (Nle).

wherein the anti-inflammatory compound is less than 100 amino acids in length.

5. **(Currently Amended)** The anti-inflammatory compound of claim 3, further comprising the variable X<sub>7</sub> immediately C-terminal to X<sub>6</sub>, wherein X<sub>7</sub> is the amino acid sequence QTE.

6. **(Currently Amended)** The anti-inflammatory compound of claim 3, wherein said compound comprises a sequence selected from the group consisting of Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu TALDWSWLQTE (SEQ ID NO:28), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:29), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu TALDWSWL (SEQ ID NO:30), Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ALDWSWLQTE (SEQ ID NO:31), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:32), Leu-Asp-Trp-Ser-Trp-Leu LDWSWL (SEQ ID NO:33), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr TALDWSWLQT (SEQ ID NO:34), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln TALDWSWLQ (SEQ ID NO:35), Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr ALDWSWLQT (SEQ ID NO:36), Leu-Asp-Trp-Ser-Trp-Leu-Gln LDWSWLQ (SEQ ID NO:37), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr LDWSWLQT (SEQ ID NO:38), Ala-Asp-Trp-Ser-Trp-Leu ADWSWL (SEQ ID NO:39), Leu-Asp-Trp-Ser-Trp-Ala LDWSWA (SEQ ID NO:40), Ala-Asp-Trp-Ser-Trp-Ala ADWSWA (SEQ ID NO:41), Leu-Asp-Phe-Ser-Trp-Leu LDFSWL (SEQ ID NO:42), Leu-Asp-Tyr-Ser-Trp-Leu LDYSWL (SEQ ID NO:43), Leu-Asp-Trp-Ala-Trp-Leu LDWAWL (SEQ ID NO:44), Leu-Asp-Trp-Glu-Trp-Leu LDWEWL (SEQ ID NO:45), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu TAADWSWLQTE (SEQ ID NO:46), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ADWSWLQTE (SEQ ID NO:47), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu TAADWSWL (SEQ ID NO:48), Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu AADWSWLQTE (SEQ ID NO:49), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ADWSWLQTE (SEQ ID NO:50), Ala-Asp-Trp-Ser-Trp-Leu ADWSWL (SEQ ID NO:51), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr TAADWSWLQT (SEQ ID NO:52), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln TAADWSWLQ (SEQ ID NO:53), Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr AADWSWLQT (SEQ ID NO:54), Ala-Asp-Trp-Ser-Trp-Leu-Gln ADWSWLQ (SEQ ID NO:55), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr ADWSWLQT (SEQ ID NO:56), Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ALDWSWAQTE (SEQ ID NO:57), Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu LDWSWAQTE (SEQ ID NO:58), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala TALDWSWA (SEQ ID NO:59), Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ALDWSWAQTE (SEQ ID NO:60), Leu-

Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu LDWSWAQTE (SEQ ID NO:61), Leu-Asp-Trp-Ser-Trp-Ala LDWSWA (SEQ ID NO:62), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr TALDWSWAQT (SEQ ID NO:63), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln TALDWSWAQ (SEQ ID NO:64), Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr ALDWSWAQT (SEQ ID NO:65), Leu-Asp-Trp-Ser-Trp-Ala-Gln LDWSWAQ (SEQ ID NO:66), Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr LDWSWAQT (SEQ ID NO:67), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu TAADWSWAQTE (SEQ ID NO:68), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ADWSWAQTE (SEQ ID NO:69), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala TAADWSWA (SEQ ID NO:70), Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu AADWSWAQTE (SEQ ID NO:71), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ADWSWAQTE (SEQ ID NO:72), Ala-Asp-Trp-Ser-Trp-Ala ADWSWA (SEQ ID NO:73), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr TAADWSWAQT (SEQ ID NO:74), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln TAADWSWAQ (SEQ ID NO:75), Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr AADWSWAQT (SEQ ID NO:76), Ala-Asp-Trp-Ser-Trp-Ala-Gln ADWSWAQ (SEQ ID NO:77), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr ADWSWAQT (SEQ ID NO:78), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu TALDFS WLQTE (SEQ ID NO:79), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu LDFS WLQTE (SEQ ID NO:80), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu TALDFS WL (SEQ ID NO:81), Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu ALDFS WLQTE (SEQ ID NO:82), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu LDFS WLQTE (SEQ ID NO:83), Leu-Asp-Phe-Ser-Trp-Leu LDFS WL (SEQ ID NO:84), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr TALDFS WLQT (SEQ ID NO:85), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln TALDFS WLQ (SEQ ID NO:86), Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr ALDFS WLQT (SEQ ID NO:87), Leu-Asp-Phe-Ser-Trp-Leu-Gln LDFS WLQ (SEQ ID NO:88), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr LDFS WLQT (SEQ ID NO:89), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu TALDY SWLQTE (SEQ ID NO:90), Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu LDY SWLQTE (SEQ ID NO:91), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu TALDY SWL (SEQ ID NO:92), Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu ALDY SWLQTE (SEQ ID NO:93), Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu LDY SWLQTE (SEQ ID NO:94), Leu-Asp-Tyr-Ser-Trp-Leu LDY SWL (SEQ ID NO:95), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr TALDY SWLQT (SEQ ID NO:96), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln TALDY SWLQ (SEQ ID NO:97), Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr ALDY SWLQT (SEQ ID NO:98), Leu-Asp-Tyr-Ser-Trp-Leu-Gln LDY SWLQ (SEQ ID NO:99), Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr LDY SWLQT (SEQ ID NO:100), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu TALDWAWLQTE (SEQ ID NO:101), Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu LDWAWLQTE (SEQ ID NO:102), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu TALDWAWL (SEQ ID NO:103), Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu ALDWAWLQTE (SEQ ID NO:104), Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu LDWAWLQTE (SEQ ID NO:105), Leu-

Asp-Trp-Ala-Trp-Leu LDWAWL (SEQ ID NO:106), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr TALDWAWLQT (SEQ ID NO:107), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln TALDWAWLQ (SEQ ID NO:108), Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr ALDWAWLQT (SEQ ID NO:109), Leu-Asp-Trp-Ala-Trp-Leu-Gln LDWAWLQ (SEQ ID NO:110), Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr LDWAWLQT (SEQ ID NO:111), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu TALDWEWLQTE (SEQ ID NO:112), Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu LDWEWLQTE (SEQ ID NO:113), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu TALDWEWL (SEQ ID NO:114), Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu ALDWEWLQTE (SEQ ID NO:115), Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu LDWEWLQTE (SEQ ID NO:116), Leu-Asp-Trp-Glu-Trp-Leu LDWEWL (SEQ ID NO:117), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr TALDWEWLQT (SEQ ID NO:118), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln TALDWEWLQ (SEQ ID NO:119), Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr ALDWEWLQT (SEQ ID NO:120), Leu-Asp-Trp-Glu-Trp-Leu-Gln LDWEWLQ (SEQ ID NO:121), and Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr LDWEWLQT (SEQ ID NO:122).

7. **(Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> consists of 6-12 amino acid residues.

8. **(Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> consists of 6-10 amino acid residues.

9. **(Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> comprises at least five basic amino acid residues.

10. **(Previously Presented)** The anti-inflammatory compound of claim 7, wherein X<sub>a</sub> comprises at least five amino acid residues independently selected from L-Arginine, D-Arginine, L-Lysine and D-Lysine.

11. **(Currently Amended)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> is selected from the group consisting of Arg-Arg-Met-Lys-Trp-Lys-Lys RRMKWKK (SEQ ID NO:123), Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg YGRKKRRQRRR (SEQ ID NO:124), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg ygrkkrrqrrr (SEQ ID NO:125), Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg YARKARRQARR (SEQ ID NO:126), D-Tyr-D-Ala-D-Arg-D-Lys-D-Ala-D-Arg-D-Arg-D-Gln-D-Ala-D-Arg-D-Arg yarkarrqarr (SEQ ID NO:127), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg YARAARRAARR (SEQ ID NO:128), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-

D-Arg-D-Ala-D-Ala-D-Arg-D-Arg ~~yaraaaffaaff~~ (SEQ ID NO:129), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys ~~mmkwkk~~ (SEQ ID NO:130), Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRR~~ (SEQ ID NO:149), Arg-Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRRR~~ (SEQ ID NO:150), Arg-Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRRRR~~ (SEQ ID NO:151), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRRRRR~~ (SEQ ID NO:152), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRRRRRR~~ (SEQ ID NO:153), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg ~~RRRRRRRRRRR~~ (SEQ ID NO:154), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~fffff~~ (SEQ ID NO:155), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~ffffff~~ (SEQ ID NO:156), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~ffffff~~ (SEQ ID NO:157), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~ffffff~~ (SEQ ID NO:158), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~ffffff~~ (SEQ ID NO:159), and D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg ~~ffffff~~ (SEQ ID NO:160).

12. **(Currently Amended)** An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of Arg-Arg-Met-Lys-Trp-Lys-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~RRMKWKKTALDWSWLQTE~~ (SEQ ID NO:131), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~mmkwkkTALDWSWLQTE~~ (SEQ ID NO:132), Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~YGRKKRRQRRRTALDWSWLQTE~~ (SEQ ID NO:133), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~ygrkkrrrrTALDWSWLQTE~~ (SEQ ID NO:134), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~TTTTTALDWSWLQTE~~ (SEQ ID NO:135), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~RRRRRRRTALDWSWLQTE~~ (SEQ ID NO:136), Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~YARKARRQARRTALDWSWLQTE~~ (SEQ ID NO:137), D-Tyr-D-Ala-D-Arg-D-Lys-D-Ala-D-Arg-D-Arg-D-Gln-D-Ala-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~yarkarrqarrTALDWSWLQTE~~ (SEQ ID NO:138), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~YARAARRAARRTALDWSWLQTE~~ (SEQ ID NO:139), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ~~yaraaaffaaffTALDWSWLQTE~~ (SEQ ID NO:140), Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu ~~YGRKKRRQRRRLDWSWL~~ (SEQ ID NO:141), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu ~~ygrkkrrrrLDWSWL~~ (SEQ ID NO:142), Arg-Arg-Met-Lys-Trp-Lys-Lys-Leu-Asp-Trp-Ser-

Trp-Leu RRMKWKKLDWSWL (SEQ ID NO:143), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-Leu-Asp-Trp-Ser-Trp-Leu ~~rrmkwkkLDWSWL~~ (SEQ ID NO:144), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu ~~rrrrrrLDWSWL~~ (SEQ ID NO:145), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu YARAARRAARRLDWSWL (SEQ ID NO:146), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu ~~yaraarraarrLDWSWL~~ (SEQ ID NO:147), and Arg-Arg-Arg-Arg-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu RRRRRRLDWSWL (SEQ ID NO:148).

13. **(Currently Amended)** An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of

H-Arg-Arg-Met-Lys-Trp-Lys-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H RRMKWKKTALDWSWLQTE-NH<sub>2</sub> (SEQ ID NO: 161);

H-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H YGRKKRRQRRRTALDWSWLQTE-NH<sub>2</sub> (SEQ ID NO: 162);

H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H ~~rrrrrr~~TALDWSWLQTE-NH<sub>2</sub> (SEQ ID NO: 163);

H-Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H YARKARRQARRTALDWSWLQTE-NH<sub>2</sub> (SEQ ID NO: 164);

H-Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H YARAARRAARRTALDWSWLQTE-NH<sub>2</sub> (SEQ ID NO: 165);

H-Arg-Arg-Met-Lys-Trp-Lys-Lys-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~RRMKWKKLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 166);

H-D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~rrmkwkkLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 167);

H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~rrrrrrLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 168);

H-Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~YARAARRAARRLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 169);

H-D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~yaraarraarrLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 170); and

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub>  
H ~~YGRKKRRQRRRLDWSWL~~-NH<sub>2</sub> (SEQ ID NO: 171).